.Attributes Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean consequence of 11 months, clients with metastatic intestinal lumps who received biomarker-matched treatments based upon flowing cyst DNA profiling revealed a greater professional benefit than those acquiring unmatched therapy.